Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students

SPARK has extended its influence to an additional 9.47 million students worldwide

Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors

The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission

Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO

The conflict is also triggering a widening public health emergency